Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Sep, 2017
News / General News
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Pfizer Contacts:
For MediaSally Beatty(212) [email protected]
For InvestorsChuck Triano(212) 733-3901 [email protected]
Astellas Contact:
For MediaTyler Marciniak (847) [email protected]
For InvestorsSo Sekine (847) [email protected]
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (e...
Read More
News / General News
U.S. FDA Accepts for Review Astellas’ Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy
Tokyo, Sept. 12, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Ap...
Read More
News / General News
Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of “Linaclotide" for Patients with Chronic Constipation in Japan
Tokyo, September 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for marketing approval of the guanylate cyclase-C receptor agonist “linaclotide (generic name) (brand name: Linzess® Tablets 0.25 mg)” for the additional indication of chronic constipation (other than constipa...
Read More
Aug, 2017
Nothing Found
Unfortunately, we weren't able to find a match for your search query. Please try again.
Jun, 2017
News / IR
Exploratory analysis of the Phase I/II CHRYSALIS study of gilteritinib was presented at 2017 ASCO annual meeting.
Read More
News / IR
Updated clinical data of enfortumab vedotin Phase 1 study was presented at 2017 ASCO annual meeting.
Read More
May, 2017
Nothing Found
Unfortunately, we weren't able to find a match for your search query. Please try again.
Nothing Found
Unfortunately, we weren't able to find a match for your search query. Please try again.